JP7577682B2 - ガレクチン－３の低分子阻害剤 - Google Patents

ガレクチン－３の低分子阻害剤 Download PDF

Info

Publication number
JP7577682B2
JP7577682B2 JP2021559883A JP2021559883A JP7577682B2 JP 7577682 B2 JP7577682 B2 JP 7577682B2 JP 2021559883 A JP2021559883 A JP 2021559883A JP 2021559883 A JP2021559883 A JP 2021559883A JP 7577682 B2 JP7577682 B2 JP 7577682B2
Authority
JP
Japan
Prior art keywords
alkyl
independently
diseases
conditions
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527395A (ja
JPWO2020210308A5 (https=
JP2022527395A5 (https=
Inventor
リウ，チュンジアン
フォン，ジエンシン
デバステール，プラティク
ムルゲサン，ナテサン
エイ エルズワース，ブルース
レゲイロ－レン，アリシア
ジェタナンド ナラ，スシール
ラオ ジャラガム，プラサダ
パンダ，マノランジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022527395A publication Critical patent/JP2022527395A/ja
Publication of JPWO2020210308A5 publication Critical patent/JPWO2020210308A5/ja
Publication of JP2022527395A5 publication Critical patent/JP2022527395A5/ja
Application granted granted Critical
Publication of JP7577682B2 publication Critical patent/JP7577682B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021559883A 2019-04-10 2020-04-08 ガレクチン－３の低分子阻害剤 Active JP7577682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831753P 2019-04-10 2019-04-10
US62/831,753 2019-04-10
PCT/US2020/027203 WO2020210308A1 (en) 2019-04-10 2020-04-08 Small molecule inhibitors of galectin-3

Publications (4)

Publication Number Publication Date
JP2022527395A JP2022527395A (ja) 2022-06-01
JPWO2020210308A5 JPWO2020210308A5 (https=) 2023-04-17
JP2022527395A5 JP2022527395A5 (https=) 2023-04-17
JP7577682B2 true JP7577682B2 (ja) 2024-11-05

Family

ID=70476468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559883A Active JP7577682B2 (ja) 2019-04-10 2020-04-08 ガレクチン－３の低分子阻害剤

Country Status (6)

Country Link
US (1) US12269819B2 (https=)
EP (1) EP3953349A1 (https=)
JP (1) JP7577682B2 (https=)
KR (1) KR102890853B1 (https=)
CN (1) CN113710665A (https=)
WO (1) WO2020210308A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
EP4010348B1 (en) 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
CA3148365A1 (en) 2019-08-29 2021-03-04 Martin Bolli Alpha-d-galactopyranoside derivatives
EP4149939A1 (en) * 2020-05-11 2023-03-22 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
ES3014851T3 (en) 2020-10-06 2025-04-25 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
KR20230104190A (ko) * 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
KR20230145111A (ko) 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
PL4301748T3 (pl) * 2021-03-03 2025-09-08 Idorsia Pharmaceuticals Ltd Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503660A (ja) 2015-01-30 2018-02-08 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
WO2018209255A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2018209276A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US9021050B2 (en) 2012-08-31 2015-04-28 Yume, Inc. Network service system and method with off-heap caching
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
JP6844991B2 (ja) 2015-11-10 2021-03-17 サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． ジッパーを有する伸縮性衣類の製法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503660A (ja) 2015-01-30 2018-02-08 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
WO2018209255A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2018209276A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3

Also Published As

Publication number Publication date
WO2020210308A1 (en) 2020-10-15
US20220144818A1 (en) 2022-05-12
JP2022527395A (ja) 2022-06-01
CN113710665A (zh) 2021-11-26
EP3953349A1 (en) 2022-02-16
KR102890853B1 (ko) 2025-11-24
KR20210150485A (ko) 2021-12-10
US12269819B2 (en) 2025-04-08

Similar Documents

Publication Publication Date Title
JP7577682B2 (ja) ガレクチン－３の低分子阻害剤
JP6790183B2 (ja) Ａｓｋ１阻害剤の固体形態
CN114846005B (zh) Shp2抑制剂及其应用
TWI657071B (zh) 芳基醚及其用途
TWI912419B (zh) 羥肟酸酯化合物、其製備方法及其應用
KR102609431B1 (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
WO2019211585A1 (en) FACTOR XIIa INHIBITORS
CN114423751A (zh) 用作选择性aurora a抑制剂的新型杂环化合物
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
JP7478165B2 (ja) ガレクチン－３の低分子阻害剤
CN107548389A (zh) 环丙烷甲酸衍生物及其药学用途
JP7628348B2 (ja) Ｔｙｋ２阻害剤としてのヘテロアリール化合物、その組成物及び用途
CN112513041B (zh) 三环化合物
JP7772718B2 (ja) ガレクチン－３阻害剤
CN112312908A (zh) Oga抑制剂化合物
JP7677995B2 (ja) ガレクチン－３の低分子阻害剤
JP2025525481A (ja) Ｔｙｋ２／ｊａｋ１の阻害剤としてのヘテロアリール化合物、その組成物および適用
HK40066473A (zh) 用作选择性aurora a抑制剂的新型杂环化合物
WO2025252235A1 (zh) 一种用于调节β2整联蛋白的化合物及其药物组合物
TWI640518B (zh) 作爲ｒａｆ激酶抑制劑的稠合三環化合物
HK40103849A (zh) 作为mek抑制剂的3，4-二氢-2，7-萘啶-1，6(2h，7h)-二酮化合物
JP2022511094A (ja) ガレクチン－３の低分子阻害剤
HK40048874B (en) Factor xiia inhibitors
HK40048874A (en) Factor xiia inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241023

R150 Certificate of patent or registration of utility model

Ref document number: 7577682

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150